Skip to main content
Erschienen in: World Journal of Urology 5/2018

27.01.2018 | Original Article

Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy

verfasst von: Sascha Kaufmann, Giorgio I. Russo, Fabian Bamberg, Lorenz Löwe, Giuseppe Morgia, Konstantin Nikolaou, Arnulf Stenzl, Stephan Kruck, Jens Bedke

Erschienen in: World Journal of Urology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the detection rate among three different targeted biopsy approaches of robot-assisted MRI/TRUS fusion (RA-TB), mpMRI in-bore (MRGB), cognitive fusion guidance biopsy (COG-TB) for the detection of prostate cancer (PC) and clinically significant PC (csPC).

Methods

Between 2014 and 2016, 156 patients with a lesion on mpMRI, performed in accordance with ESUR guidelines, due to cancer suspicion or on-going cancer suspicion after prior negative prostate biopsy, underwent targeted biopsy with RA-TB, MRGB or COG-TB. All lesions were rated according to PI-RADS v2. We compared detection rates between techniques. Models were constructed to predict the detection of overall PC and csPC and using a 1000 boot-strap sample.

Results

In the all cohort, 73, 45 and 38 patients underwent RA-TB, MRGB or COG-TB, respectively. Overall PC was found in 39 (52.42%), 23 (51.11%) and 11 (28.95%) (p = 0.04) patients of RA-TB, MRGB and COG-TB arm, respectively. As concerning the detection of csPC, it was found in 26 (35.62%),18 (40.0%) and 9 (23.68%) patients of RA-TB, MRGB and COG-TB arm (p = 0.27). Model 1 showed that RA-TB [OR: 10.08 (95% CI 1.95–51.97); p < 0.01] and MRGB [OR: 12.88 (95% CI 2.36–70.25); p < 0.01] were associated with overall PC detection in TB, while only MRGB was associated with csPC at TB (model 2) [OR: 5.72; (95% CI 1.40–23.35); p < 0.01]. The c-index for model 1 and model 2 was 0.86 and 0.85, respectively. We did not report significant complications between groups.

Conclusion

In-bore biopsy and MRI/TRUS fusion-guided biopsy showed greater accuracy in detecting PC compared to cognitive fusion as modeled in a newly established normogram.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, van den Broeck T, van den Poel HG, van den Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003 CrossRefPubMed Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, van den Broeck T, van den Poel HG, van den Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://​doi.​org/​10.​1016/​j.​eururo.​2016.​08.​003 CrossRefPubMed
3.
Zurück zum Zitat Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouviere O (2017) What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the european association of urology prostate cancer guidelines panel. Eur Urol 72(2):250–266. https://doi.org/10.1016/j.eururo.2017.02.026 CrossRefPubMed Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouviere O (2017) What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the european association of urology prostate cancer guidelines panel. Eur Urol 72(2):250–266. https://​doi.​org/​10.​1016/​j.​eururo.​2017.​02.​026 CrossRefPubMed
5.
Zurück zum Zitat Schiavina R, Vagnoni V, D’Agostino D, Borghesi M, Salvaggio A, Giampaoli M, Pultrone CV, Saraceni G, Gaudiano C, Vigo M, Bianchi L, Dababneh H, La Manna G, Chessa F, Romagnoli D, Martorana G, Brunocilla E, Porreca A (2017) “In-bore” MRI-guided prostate biopsy using an endorectal nonmagnetic device: a prospective study of 70 consecutive patients. Clin Genitourin Cancer 15(3):417–427. https://doi.org/10.1016/j.clgc.2017.01.013 CrossRefPubMed Schiavina R, Vagnoni V, D’Agostino D, Borghesi M, Salvaggio A, Giampaoli M, Pultrone CV, Saraceni G, Gaudiano C, Vigo M, Bianchi L, Dababneh H, La Manna G, Chessa F, Romagnoli D, Martorana G, Brunocilla E, Porreca A (2017) “In-bore” MRI-guided prostate biopsy using an endorectal nonmagnetic device: a prospective study of 70 consecutive patients. Clin Genitourin Cancer 15(3):417–427. https://​doi.​org/​10.​1016/​j.​clgc.​2017.​01.​013 CrossRefPubMed
6.
Zurück zum Zitat Mischinger J, Kaufmann S, Russo GI, Harland N, Rausch S, Amend B, Scharpf M, Loewe L, Todenhoefer T, Notohamiprodjo M, Nikolaou K, Stenzl A, Bedke J, Kruck S (2017) Targeted versus systematic robot-assisted transperineal MRI-TRUS fusion prostate biopsy. BJU Int. https://doi.org/10.1111/bju.14089 PubMed Mischinger J, Kaufmann S, Russo GI, Harland N, Rausch S, Amend B, Scharpf M, Loewe L, Todenhoefer T, Notohamiprodjo M, Nikolaou K, Stenzl A, Bedke J, Kruck S (2017) Targeted versus systematic robot-assisted transperineal MRI-TRUS fusion prostate biopsy. BJU Int. https://​doi.​org/​10.​1111/​bju.​14089 PubMed
8.
Zurück zum Zitat Kaufmann S, Mischinger J, Amend B, Rausch S, Adam M, Scharpf M, Fend F, Kramer U, Notohamiprodjo M, Nikolaou K, Stenzl A, Bedke J, Kruck S (2017) First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy. World J Urol 35(7):1023–1029. https://doi.org/10.1007/s00345-016-1970-8 CrossRefPubMed Kaufmann S, Mischinger J, Amend B, Rausch S, Adam M, Scharpf M, Fend F, Kramer U, Notohamiprodjo M, Nikolaou K, Stenzl A, Bedke J, Kruck S (2017) First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy. World J Urol 35(7):1023–1029. https://​doi.​org/​10.​1007/​s00345-016-1970-8 CrossRefPubMed
10.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y, Consortium S (2013) Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol 64(4):544–552. https://doi.org/10.1016/j.eururo.2013.03.030 CrossRefPubMed Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y, Consortium S (2013) Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol 64(4):544–552. https://​doi.​org/​10.​1016/​j.​eururo.​2013.​03.​030 CrossRefPubMed
14.
Zurück zum Zitat Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M, Bitker MO, Leroy X, Mege-Lechevallier F, Comperat E, Ouzzane A, Lemaitre L (2013) Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy–prospective multicenter study. Radiology 268(2):461–469. https://doi.org/10.1148/radiol.13121501 CrossRefPubMed Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M, Bitker MO, Leroy X, Mege-Lechevallier F, Comperat E, Ouzzane A, Lemaitre L (2013) Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy–prospective multicenter study. Radiology 268(2):461–469. https://​doi.​org/​10.​1148/​radiol.​13121501 CrossRefPubMed
15.
Zurück zum Zitat Labanaris AP, Engelhard K, Zugor V, Nutzel R, Kuhn R (2010) Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis 13(1):65–70. https://doi.org/10.1038/pcan.2009.41 CrossRefPubMed Labanaris AP, Engelhard K, Zugor V, Nutzel R, Kuhn R (2010) Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis 13(1):65–70. https://​doi.​org/​10.​1038/​pcan.​2009.​41 CrossRefPubMed
16.
Zurück zum Zitat Kaufmann S, Kruck S, Kramer U, Gatidis S, Stenzl A, Roethke M, Scharpf M, Schilling D (2015) Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies. Urol Int 94(3):319–325. https://doi.org/10.1159/000365397 CrossRefPubMed Kaufmann S, Kruck S, Kramer U, Gatidis S, Stenzl A, Roethke M, Scharpf M, Schilling D (2015) Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies. Urol Int 94(3):319–325. https://​doi.​org/​10.​1159/​000365397 CrossRefPubMed
18.
Zurück zum Zitat Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, Claussen CD, Stenzl A, Schlemmer HP, Schilling D (2012) MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 30(2):213–218. https://doi.org/10.1007/s00345-011-0675-2 CrossRefPubMed Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, Claussen CD, Stenzl A, Schlemmer HP, Schilling D (2012) MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 30(2):213–218. https://​doi.​org/​10.​1007/​s00345-011-0675-2 CrossRefPubMed
19.
Zurück zum Zitat Venderink W, van der Leest M, van Luijtelaar A, van de Ven WJM, Futterer JJ, Sedelaar JPM, Huisman HJ (2017) Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer. World J Urol. https://doi.org/10.1007/s00345-017-2085-6 PubMedPubMedCentral Venderink W, van der Leest M, van Luijtelaar A, van de Ven WJM, Futterer JJ, Sedelaar JPM, Huisman HJ (2017) Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer. World J Urol. https://​doi.​org/​10.​1007/​s00345-017-2085-6 PubMedPubMedCentral
22.
Zurück zum Zitat Lemeshow S, Hosmer DW Jr (1982) A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 115(1):92–106CrossRefPubMed Lemeshow S, Hosmer DW Jr (1982) A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 115(1):92–106CrossRefPubMed
23.
24.
Zurück zum Zitat Kroenig M, Schaal K, Benndorf M, Soschynski M, Lenz P, Krauss T, Drendel V, Kayser G, Kurz P, Werner M, Wetterauer U, Schultze-Seemann W, Langer M, Jilg CA (2016) Diagnostic Accuracy of robot-guided, software based transperineal MRI/TRUS fusion biopsy of the prostate in a high risk population of previously biopsy negative men. Biomed Res Int 2016:2384894. https://doi.org/10.1155/2016/2384894 CrossRefPubMedPubMedCentral Kroenig M, Schaal K, Benndorf M, Soschynski M, Lenz P, Krauss T, Drendel V, Kayser G, Kurz P, Werner M, Wetterauer U, Schultze-Seemann W, Langer M, Jilg CA (2016) Diagnostic Accuracy of robot-guided, software based transperineal MRI/TRUS fusion biopsy of the prostate in a high risk population of previously biopsy negative men. Biomed Res Int 2016:2384894. https://​doi.​org/​10.​1155/​2016/​2384894 CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Wegelin O, van Melick HHE, Hooft L, Bosch J, Reitsma HB, Barentsz JO, Somford DM (2017) Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. is there a preferred technique? Eur Urol 71(4):517–531. https://doi.org/10.1016/j.eururo.2016.07.041 CrossRefPubMed Wegelin O, van Melick HHE, Hooft L, Bosch J, Reitsma HB, Barentsz JO, Somford DM (2017) Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. is there a preferred technique? Eur Urol 71(4):517–531. https://​doi.​org/​10.​1016/​j.​eururo.​2016.​07.​041 CrossRefPubMed
27.
Zurück zum Zitat Cantiello F, Russo GI, Cicione A, Ferro M, Cimino S, Favilla V, Perdona S, De Cobelli O, Magno C, Morgia G, Damiano R (2016) PHI and PCA3 improve the prognostic performance of PRIAS and epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol 34(4):485–493. https://doi.org/10.1007/s00345-015-1643-z CrossRefPubMed Cantiello F, Russo GI, Cicione A, Ferro M, Cimino S, Favilla V, Perdona S, De Cobelli O, Magno C, Morgia G, Damiano R (2016) PHI and PCA3 improve the prognostic performance of PRIAS and epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol 34(4):485–493. https://​doi.​org/​10.​1007/​s00345-015-1643-z CrossRefPubMed
28.
29.
Metadaten
Titel
Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy
verfasst von
Sascha Kaufmann
Giorgio I. Russo
Fabian Bamberg
Lorenz Löwe
Giuseppe Morgia
Konstantin Nikolaou
Arnulf Stenzl
Stephan Kruck
Jens Bedke
Publikationsdatum
27.01.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 5/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2189-7

Weitere Artikel der Ausgabe 5/2018

World Journal of Urology 5/2018 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.